GSK Roundup: High-Level GSK Delegation Apologizes Face-To-Face With China Ministry
This article was originally published in PharmAsia News
Executive Summary
The first face-to-face meeting of three U.K.-based GlaxoSmithKline executives with China authorities has elicited an apology from the company, according to the Public Security Ministry following the session, with Chief executive Andrew Witty set to detail steps the company has taken to address the issue on a July 24 quarterly earnings call.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.